Microbot Medical Transitions to Commercial Operations with Increased Revenue from LIBERTY System
Microbot Medical Inc. has successfully transitioned to commercial operations following the limited market release of its LIBERTY® Endovascular Robotic System, recording significant revenue growth in Q2 2026. The company has doubled its accounts and expanded into new sales territories. Key developments include robotic procedures for obesity and chronic knee pain, supported by favorable industry guidelines. The company anticipates accelerated adoption of the LIBERTY System as it continues to build its commercial infrastructure.
Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter